A 28 year old male was recently diagnosed with schizophrenia. He has a body mass index of 30, fasting triglycerides of 250mg/dL, and fasting glucose of 125mg/dL. Which of the following medications is least likely to worsen his metabolic profile?

A. Ziprasidone: Ziprasidone has a relatively low risk of weight gain, hyperglycemia, and dyslipidemia compared with other atypical antipsychotics. Its minimal effects on H1 and 5HT2C receptors make it the preferred option for patients with preexisting metabolic risk factors. B. Risperidone: Risperidone carries a moderate risk for weight gain and metabolic disturbances. While less severe than olanzapine or clozapine, it may still worsen hypertriglyceridemia, hyperglycemia, or obesity in susceptible patients. C. Olanzapine: Olanzapine has one of the highest metabolic risk profiles among atypical antipsychotics. It strongly promotes weight gain, insulin resistance, and dyslipidemia, making it unsuitable for patients with preexisting metabolic concerns. D. Quetiapine: Quetiapine has a moderate risk of weight gain and metabolic effects due to H1 and 5HT2C antagonism. While safer than olanzapine or clozapine, it is more likely than ziprasidone to exacerbate metabolic problems in high-risk patients.